Search

Your search keyword '"Tremblay, Douglas"' showing total 119 results

Search Constraints

Start Over You searched for: Author "Tremblay, Douglas" Remove constraint Author: "Tremblay, Douglas" Database MEDLINE Remove constraint Database: MEDLINE
119 results on '"Tremblay, Douglas"'

Search Results

1. Adoptive cell therapy in acute myeloid leukemia: the current landscape and emerging strategies.

2. Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis.

3. Evaluating the role of Day 14 bone marrow biopsy and European LeukemiaNet risk classification in predicting overall and relapse-free survival in acute myeloid leukemia.

4. Management of Advanced Systemic Mastocytosis: Clinical Challenges.

5. Oral Decitabine/Cedazuridine Is an Effective Ambulatory Therapy for Patients With Myelofibrosis Refractory to JAK2 Inhibitor Therapy.

6. Ven the dose matters: Venetoclax dosing in the frontline treatment of AML.

7. How to customize common data models for rare diseases: an OMOP-based implementation and lessons learned.

9. Equivalent thrombotic risk with Warfarin, Dabigatran, or Enoxaparin after failure of initial direct oral anticoagulation (DOAC) therapy.

10. Conventional Cytogenetic Analysis and Array CGH + SNP Identify Essential Thrombocythemia and Prefibrotic Primary Myelofibrosis Patients Who Are at Risk for Disease Progression.

11. Systematic review and meta-analysis evaluating clinical outcomes in adult acute myeloid leukemia patients with central nervous system involvement.

12. Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management.

13. Decreased patency of transjugular intrahepatic portosystemic shunts performed for splanchnic vein thrombosis in patients with myeloproliferative neoplasms.

15. Exclusion of Acute Myeloid Leukemia Patients with Central Nervous System Involvement from Clinical Trials: An Analysis of the National Institutes of Health Clinical Trials Registry from 2012 to 2022.

17. Cytoreduction for ET and PV: who, what, when, and how?

18. Multi-institutional analysis of outcomes in acute myeloid leukemia patients with central nervous system involvement.

19. An overlooked mimic? Autoimmune myelofibrosis-A scoping review of the literature.

20. The core concepts of core binding factor acute myeloid leukemia: Current considerations for prognosis and treatment.

21. Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia.

23. Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor.

24. Emerging Treatment Options for Myelofibrosis: Focus on Anemia.

25. Pharmacotherapeutic advances for splenomegaly in myelofibrosis.

26. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.

27. New Treatments for Myelofibrosis.

28. Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs.

29. Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide.

30. Efficacy and Safety of Pacritinib vs Placebo for Patients With Severe COVID-19: A Phase 2 Randomized Clinical Trial.

31. Impact of Fluoroquinolone Prophylaxis on Neutropenic Fever, Infections, and Antimicrobial Resistance in Newly Diagnosed AML Patients.

32. Splanchnic vein thrombosis associated with myeloproliferative neoplasms.

33. The Quantification and Significance of Extramedullary Hematopoiesis Seen on Liver Biopsy Specimens.

34. Anagrelide for platelet-directed cytoreduction in polycythemia vera: Insights into utility and safety outcomes from a large multi-center database.

35. Thrombocytopenia in Patients With Myelofibrosis: Pathogenesis, Prevalence, Prognostic Impact, and Treatment.

36. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

38. Momelotinib for the treatment of myelofibrosis with anemia.

39. Addressing symptom burden in myeloproliferative neoplasms.

40. Contemporary and future strategies in polycythemia vera.

41. Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

43. Low-risk polycythemia vera and essential thrombocythemia: management considerations and future directions.

44. Novel treatments for myelofibrosis: beyond JAK inhibitors.

45. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.

46. Combined Drug Targeting of p53-dependent and -independent Pathways Depletes Myelofibrosis Hematopoietic Stem/Progenitor Cells.

47. Emerging drugs for the treatment of myelofibrosis: phase II & III clinical trials.

48. Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients.

49. Care disruptions among patients with lung cancer: A COVID-19 and cancer outcomes study.

50. The utility and complications of plasma administration in cirrhotic patients undergoing minimally invasive procedures.

Catalog

Books, media, physical & digital resources